Champions Oncology Inc (CSBR)vsVertex Pharmaceuticals Inc (VRTX)
CSBR
Champions Oncology Inc
$4.92
+1.86%
HEALTHCARE · Cap: $66.95M
VRTX
Vertex Pharmaceuticals Inc
$529.69
+1.66%
HEALTHCARE · Cap: $126.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 20650% more annual revenue ($12.59B vs $60.66M). VRTX leads profitability with a 35.0% profit margin vs -1.9%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
CSBR
Avoid23
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+43.2%
Fair Value
$10.38
Current Price
$4.92
$5.46 discount
Margin of Safety
+45.0%
Fair Value
$952.30
Current Price
$529.69
$422.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Trading at 17.6x book value
Smaller company, higher risk/reward
ROE of -53.3% — below average capital efficiency
Earnings declined 61.1%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CSBR
CSBR has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : CSBR
The primary concerns for CSBR are Price/Book, Market Cap, Return on Equity. Debt-to-equity of 2.82 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CSBR profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
CSBR carries more volatility with a beta of 0.44 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 23/100), backed by strong 35.0% margins and 12.5% revenue growth. CSBR offers better value entry with a 43.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Champions Oncology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. The company is headquartered in Hackensack, New Jersey.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?